Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Aerocrine
Solna, Sweden
- Ownership
- Private
- Development stage
- Other
01
Overview
Aerocrine pioneered the measurement of fractional exhaled nitric oxide (FeNO) as a non-invasive biomarker for airway inflammation. Its devices—NIOX MINO®, NIOX VERO®, and earlier models—are used globally to aid in asthma diagnosis and management. The company’s products have been recommended by NICE in the UK and are widely adopted in clinical practice[1][2][3]. Clinical results show that FeNO testing improves asthma diagnosis accuracy and helps guide anti-inflammatory therapy. Over 50 million FeNO tests have been performed with this technology[4].
- Therapeutic areas
- Pulmonology
- Modalities
- DeviceDiagnostic device (FeNO testing)
- Industry
- Metabolite Diagnostics
Beyond the preview
Go deeper on Aerocrine.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aerocrine.